Otros idiomas Edgewise Therapeutics, Inc.

Acciones

EWTX

US28036F1057

Tiempo real estimado Cboe BZX Otros sitios de cotización 20:07:39 26/06/2024			Varia. Cinco días.	Varia. 1 de enero.
16,97 ^USD	-2,42 %		+0,89 %	+55,03 %

10/05	EDGEWISE THERAPEUTICS, INC. : Recibe una recomendación de compra del Wedbush	ZM
09/05	Edgewise Therapeutics, Inc. Resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to S&P Pharmaceuticals Select Industry Index	24/06
Edgewise Therapeutics : Corporate Overview, May 2024	30/05
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024	13/05
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024	10/05
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors	07/05
Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors	07/05
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy	07/05
Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial	06/05
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)	06/05
Edgewise Therapeutics, Inc Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy	06/05
Edgewise Receives European Medicines Agency Orphan Drug Designations for Sevasemten for the Treatment of Becker and Duchenne Muscular Dystrophies	24/04
Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	23/04
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies	23/04
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results	19/04
Sector Update: Health Care Stocks Mixed Premarket Tuesday	16/04
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy	16/04
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results April 2024	16/04
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	15/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Edgewise Therapeutics, Inc.

Acciones

EWTX

US28036F1057

Otros idiomas

Filtros